Abdel Aziz RS, Radwan EM, Fouad AM, Abdellateif MS, Elfishawi S. Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients. World J Clin Oncol 2025; 16(6): 107271 [DOI: 10.5306/wjco.v16.i6.107271]
Corresponding Author of This Article
Mona S Abdellateif, Department of Cancer Biology, National Cancer Institute, Cairo University, 1 Fom Elkhaligue, Cairo 11796, Egypt. mona.sayed@nci.cu.edu.eg
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2025; 16(6): 107271 Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.107271
Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients
Rania S Abdel Aziz, Enas M Radwan, Abdelhamid M Fouad, Mona S Abdellateif, Sally Elfishawi
Rania S Abdel Aziz, Enas M Radwan, Sally Elfishawi, Clinical Pathology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Abdelhamid M Fouad, Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Mona S Abdellateif, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Mona S Abdellateif, Basic Medical Science, Galala University, Suez 15888, Egypt
Co-first authors: Rania S Abdel Aziz and Enas M Radwan.
Author contributions: Abdel Aziz RS and Elfishawi S conceptualized the research and performed the molecular work; Radwan EM performed flow cytometry; Fouad AM performed patient management and follow-up; Abdellateif MS performed molecular work and statistical analysis. All authors wrote the and revised the manuscript according to their specialties. Abdel Aziz RS and Radwan EM contributed equally to this work as co-first authors.
Institutional review board statement: Ethical approval (No. CP2501-503-076-195) of the current study was obtained from the review board of NCI, Cairo University.
Informed consent statement: Informed consent was obtained from each patient before enrollment in the study.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at mona.sayed@nci.cu.edu.eg.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mona S Abdellateif, Department of Cancer Biology, National Cancer Institute, Cairo University, 1 Fom Elkhaligue, Cairo 11796, Egypt. mona.sayed@nci.cu.edu.eg
Received: March 20, 2025 Revised: April 17, 2025 Accepted: May 16, 2025 Published online: June 24, 2025 Processing time: 93 Days and 4.2 Hours
Abstract
BACKGROUND
The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms.
AIM
To assess the significance of SOX11 gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML.
METHODS
This retrospective study enrolled 102 adults with AML. SOX11 gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients’ clinical features, response to treatment, and survival rates.
RESULTS
Increased SOX11 expression was significantly associated with the presence of the FLT3-ITD mutation (P < 0.001), the FAB-M2 subtype (P = 0.008), and cytogenetic abnormalities (P = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival.
CONCLUSION
SOX11 expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.
Core Tip: Higher SOX11 expression correlated with FAB M2 and abnormal cytogenetics in acute myeloid leukemia (AML) patients. The association of higher SOX11 expression with the FLT-ITD mutation could be useful in identifying high-risk AML patients who may benefit from targeted or more intensive therapies. Furthermore, the association of higher SOX11 expression with cytogenetic abnormalities might have implications in predicting risk of translocation development and relapse in patients undertaking high risk therapy.
